BioSpace News Archive

Transparency Market Research has published a new report on the biological imaging reagents market for the forecast period of 2019–2027.

Obatala Sciences, a biotechnology company that manufactures stem cell and hydrogel products to enable next-generation therapeutics discovery, has been granted an exclusive license from Harvard University to commercialize innovations that enable the study of human fat tissue in vitro.

Harvard University has granted an exclusive license to biotechnology company Obatala Sciences to commercialize innovations that enable the study of human fat tissue in vitro.

Relay Therapeutics, Inc. is scheduled to participate in fireside chats at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 3:50 pm ET and at the JMP Securities Life Science Conference on Thursday, June 17, 2021 at 10:30 am ET.

Evidenced-based expert algorithm separates EDS-FLU, marketed as XHANCE®, from standard intranasal steroid sprays, recommending it for patients with nasal polyps whose symptoms persist after using standard intranasal steroid sprays

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that senior management will present at the following upcoming virtual investor conferences

Prelude Therapeutics Inc., a clinical-stage precision oncology company, announced that members of its management team will participate in two upcoming virtual investor conferences

Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced that management plans to present and host investor meetings at the Raymond James Human Health Innovations Conference on June 23rd.

BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, provides an update on the overall survival data on its previously disclosed advanced breast cancer patients.

Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that the company will participate in the upcoming Goldman Sachs 42nd Annual Global Healthcare Conference.